Announcement: Eli Lilly’s Gene Editor Cuts Cholesterol 62% in First Human Trial

Last updated: 26/06/2026 08:26

0 Min Read

Eli Lilly's experimental gene-editing therapy VERV-102 achieved a 62% reduction in cholesterol levels at the highest dose in Phase 1 clinical trials. The single-dose treatment targets the PCSK9 gene to potentially provide permanent cholesterol control. — Photo by Supplements On Demand on Pexels (Pexels License)

1 min read|33 words

🧬 BREAKTHROUGH: Eli Lilly's gene-editing therapy cuts cholesterol by 62% with a single dose! VERV-102 targets the PCSK9 gene for potentially permanent treatment. Could revolutionize cardiovascular care.

Read the full article on GMJ Newsroom →

Was this article helpful?

GMJ Brief · Announcement

📰 Read the full article: Eli Lilly’s Gene Editor Cuts Cholesterol 62% in First Human Trial →

Share This Article

ByProf. Giorgi Pkhakadze

Follow:

Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.